Key facts
as of Sep 2026- City Therapeutics’s last known valuation is $285.5M.
- It has raised $139.5M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($135.0M) in Oct 2024.
- Notable investors include Fidelity Management & Research Company, ARCH Venture Partners, The Invus Group, Rock Springs Capital, Slate Path Capital — 8 tracked in total.
- 1 institutional filer reports fund marks on City Therapeutics across 1 filings.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for City Therapeutics
Recorded secondary trades
No secondary trades in City Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
1 filers · latest May 20261 SEC-registered fund reported 1 fair-value mark on City Therapeutics between May 2026 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
1 roundsAbout City Therapeutics
Operator of a biotechnology company intended to develop innovative, precise, and effective treatments for a wide range of diseases. The company focuses on creating medicines that use RNAi technology to silence harmful gene expression by targeting and degrading messenger RNA (mRNA), enabling healthcare professionals to offer more targeted and more effective treatment options for their patients, especially in disease areas with limited treatment.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2024
- Employees
- 47
- Website
- citytx.com/
- Ownership
- Privately Held (backing)